Candesartan Cilexetil Tablets, 16 mg, a) 30 count (NDC 00781-5938-31) and b) 90 count (NDC 00781-...
FDA Drug Recall #D-0659-2016 — Class III — December 31, 2015
Recall Summary
| Recall Number | D-0659-2016 |
| Classification | Class III — Low risk |
| Date Initiated | December 31, 2015 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Sandoz Inc |
| Location | Princeton, NJ |
| Product Type | Drugs |
| Quantity | 277,267 bottles |
Product Description
Candesartan Cilexetil Tablets, 16 mg, a) 30 count (NDC 00781-5938-31) and b) 90 count (NDC 00781-5938-92) bottles, Rx Only, Manufactured by Mylan Laboratories Limited Hyderabad 500 034, India for Sandoz Inc. Princeton, NJ 08540
Reason for Recall
Failed Impurities/Degradation Specifications; 9 month stability timepoint
Distribution Pattern
Nationwide
Lot / Code Information
a) 3022288 12/2015 3025988 03/2016 3025989 04/2016 3030459 08/2016 3030460 08/2016 3032087 10/2016 3032088 10/2016 3034506 12/2016 3035952 01/2017 3035953 01/2017 b) 3022287 12/2015 3025990 04/2016 3030458 08/2016 3032086 09/2016 3035954 01/2017
Other Recalls from Sandoz Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0651-2025 | Class II | Cyclophosphamide Injection 500 mg/5 mL (100 mg/... | Sep 5, 2025 |
| D-0626-2025 | Class II | Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic ... | Aug 13, 2025 |
| D-0569-2025 | Class I | Cefazolin for Injection, USP, 1 gram per vial, ... | Jun 27, 2025 |
| D-0570-2025 | Class I | Buffered Penicillin G Potassium for Injection, ... | Jun 27, 2025 |
| D-0286-2022 | Class I | Enoxaparin Sodium Injection, USP, 40 mg/0.4 mL,... | Nov 17, 2021 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.